Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.35 |
| ▸ | FUCA2 | Q9BTY2 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14708924 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL12353568 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL16609374 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL24133914 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL18517146 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL24517614 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL15958942 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL22026383 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL22620572 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 | |
| SCHEMBL13512901 | 1.00 | THRB (0.43) | THRBLMNAFUCA1FUCA2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | AMICUS THERAPEUTICS INC (US) | 2017-02-16 | — | — | US | disclosed |
| US-9481700-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-8487110-B2 | Method for preparing isofagomine and its derivatives | AMICUS THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160638-A1 | NEW METHOD FOR PREPARING ISOFAGOMINE AND ITS DERIVATIVES | ALDOA, FBP1, GALE | THRB 4008/4885LMNA 2536/4885FUCA1 7/4885 |
| US-20170044102-A1 | New Method for Preparing Isofagomine and Its Derivatives | ALDOA, FBP1, GALE | THRB 4008/4885LMNA 2536/4885FUCA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.